Anti-angiogenic therapy as a beacon of hope in the battle against pulmonary NUT midline carcinoma

Abstract

Primary pulmonary nuclear protein of the testis (NUT) midline carcinoma (NMC) is a rare and highly aggressive thoracic malignancy that poses significant diagnostic and therapeutic challenges in clinical practice. This tumor is characterized by its heterogeneous clinical presentations and poor prognosis, often evading accurate initial diagnosis. In this study, we present two cases of primary pulmonary NMC treated with an integrated therapeutic approach combining anti-angiogenic agents, platinum-based chemotherapy, and radiotherapy. This multimodal strategy achieved survival durations of 32 and 13 months, respectively, surpassing the currently reported median survival of advanced NMC. Through a systematic literature review of reported cases, we have summarized the currently used diagnostic methods and treatment modalities for NMC. Our findings suggest that multimodal therapy incorporating anti-angiogenic treatment may offer superior clinical outcomes compared to conventional monotherapy regimens, particularly for patients who are not eligible for surgery. This comprehensive investigation enhances our understanding of NMC management by elucidating diagnostic pitfalls through histopathological correlation and proposing an effective therapeutic combination that demonstrates improved survival outcomes. By providing valuable insights into the diagnosis and treatment of primary pulmonary NMC, we hope to contribute to the development of more effective strategies for managing this rare and aggressive malignancy.

Keywords

lung cancer / NUT carcinoma / diagnosis / treatment strategy / anti-angiogenic therapy

References

[1] French CA. Pathogenesis of NUT midline carcinoma. Annu Rev Pathol 2012; 7(1): 247–265

[2] French C. NUT midline carcinoma. Nat Rev Cancer 2014; 14(3): 149–150

[3] Chen M, Chen X, Zhang Y, Wang W, Jiang L. Clinical and molecular features of pulmonary NUT carcinoma characterizes diverse responses to immunotherapy, with a pathologic complete response case. J Cancer Res Clin Oncol 2023; 149(9): 6361–6370

[4] Moreno V, Saluja K, Pina-Oviedo S. NUT carcinoma: clinicopathologic features, molecular genetics and epigenetics. Front Oncol 2022; 12: 860830

[5] Mao N, Liao Z, Wu J, Liang K, Wang S, Qin S, Dou Y, Lin H, Dong X. Diagnosis of NUT carcinoma of lung origin by next-generation sequencing: case report and review of the literature. Cancer Biol Ther 2019; 20(2): 150–156

[6] Lantuejoul S, Pissaloux D, Ferretti GR, McLeer A. NUT carcinoma of the lung. Semin Diagn Pathol 2021; 38(5): 72–82

[7] Cho YA, Choi YL, Hwang I, Lee K, Cho JH, Han J. Clinicopathological characteristics of primary lung nuclear protein in testis carcinoma: a single-institute experience of 10 cases. Thorac Cancer 2020; 11(11): 3205–3212

[8] Chau NG, Ma C, Danga K, Al-Sayegh H, Nardi V, Barrette R, Lathan CS, DuBois SG, Haddad RI, Shapiro GI, Sallan SE, Dhar A, Nelson JJ, French CA. An anatomical site and genetic-based prognostic model for patients with nuclear protein in testis (NUT) midline carcinoma: analysis of 124 patients. JNCI Cancer Spectr 2020; 4(2): pkz094

[9] Han X, Liu J, Zhang Y, Tse E, Yu Q, Lu Y, Ma Y, Zheng L. Increasing the tumour targeting of antitumour drugs through anlotinib-mediated modulation of the extracellular matrix and the RhoA/ROCK signalling pathway. J Pharm Anal 2024; 14(8): 100984

[10] Hellquist H, French CA, Bishop JA, Coca-Pelaz A, Propst EJ, Paiva Correia A, Ngan BY, Grant R, Cipriani NA, Vokes D, Henrique R, Pardal F, Vizcaino JR, Rinaldo A, Ferlito A. NUT midline carcinoma of the larynx: an international series and review of the literature. Histopathology 2017; 70(6): 861–868

[11] Haefliger S, Tzankov A, Frank S, Bihl M, Vallejo A, Stebler J, Hench J. NUT midline carcinomas and their differentials by a single molecular profiling method: a new promising diagnostic strategy illustrated by a case report. Virchows Arch 2021; 478(5): 1007–1012

[12] French CA. The importance of diagnosing NUT midline carcinoma. Head Neck Pathol 2013; 7(1): 11–16

[13] Ueki H, Maeda N, Sekimizu M, Yamashita Y, Moritani S, Horibe K. A case of NUT midline carcinoma with complete response to gemcitabine following cisplatin and docetaxel. J Pediatr Hematol Oncol 2014; 36(8): e476–e480

[14] Bauer DE, Mitchell CM, Strait KM, Lathan CS, Stelow EB, Lüer SC, Muhammed S, Evans AG, Sholl LM, Rosai J, Giraldi E, Oakley RP, Rodriguez-Galindo C, London WB, Sallan SE, Bradner JE, French CA. Clinicopathologic features and long-term outcomes of NUT midline carcinoma. Clin Cancer Res 2012; 18(20): 5773–5779

[15] Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS, Turpin B, Dowlati A, Brose MS, Mascarenhas L, Federman N, Berlin J, El-Deiry WS, Baik C, Deeken J, Boni V, Nagasubramanian R, Taylor M, Rudzinski ER, Meric-Bernstam F, Sohal DPS, Ma PC, Raez LE, Hechtman JF, Benayed R, Ladanyi M, Tuch BB, Ebata K, Cruickshank S, Ku NC, Cox MC, Hawkins DS, Hong DS, Hyman DM. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018; 378(8): 731–739

[16] Kees UR, Mulcahy MT, Willoughby ML. Intrathoracic carcinoma in an 11-year-old girl showing a translocation t(15;19). J Pediatr Hematol Oncol 1991; 13(4): 459–464

[17] Prall OWJ, Thio N, Yerneni S, Kumar B, McEvoy CR. A NUT carcinoma lacking squamous differentiation and expressing TTF1. Pathology 2021; 53(5): 663–666

[18] Huang W, Zhang Y, Yang Q, Gao G, Qiu Y, Li L, Kang L. Clinical imaging of primary pulmonary nucleoprotein of the testis carcinoma. Front Med (Lausanne) 2022; 9: 1083206

[19] Kloker LD, Calukovic B, Benzler K, Golf A, Böhm S, Günther S, Horger M, Haas S, Berchtold S, Beil J, Carter ME, Ganzenmueller T, Singer S, Agaimy A, Stöhr R, Hartmann A, Duell T, Mairhofer S, Fohrer F, Reinmuth N, Zender L, Lauer UM. Case report: immunovirotherapy as a novel add-on treatment in a patient with thoracic NUT carcinoma. Front Oncol 2022; 12: 995744

[20] Zhao R, Hua Z, Hu X, Zhang Q, Zhang J, Wang J. NUT carcinoma of the lung: a case report and literature analysis. Front Oncol 2022; 12: 890338

[21] Costa BA, Maraveyas A, Wilkoff MH, Correia GSC, Tallón de Lara P, Rohs NC, Salonia J. Primary pulmonary NUT carcinoma: case illustration and updated review of literature. Clin Lung Cancer 2022; 23(4): e296–e300

[22] Agaimy A, Haller F, Renner A, Niedermeyer J, Hartmann A, French CA. Misleading germ cell phenotype in pulmonary NUT carcinoma harboring the ZNF532-NUTM1 fusion. Am J Surg Pathol 2022; 46(2): 281–288

[23] Jiang J, Ren Y, Xu C, Lin X. NUT midline carcinoma as a primary lung tumor treated with anlotinib combined with palliative radiotherapy: a case report. Diagn Pathol 2022; 17(1): 4

[24] Chen M, Yang J, Lv L, Li Y, Tang Y, Liu W, Wang W, Jiang L. Comprehensive genetic profiling of six pulmonary nuclear protein in testis carcinomas with a novel micropapillary histological subtype in two cases. Hum Pathol 2021; 115: 56–66

[25] Davis A, Mahar A, Wong K, Barnet M, Kao S. Prolonged disease control on nivolumab for primary pulmonary NUT carcinoma. Clin Lung Cancer 2021; 22(5): e665–e667

[26] Zhang Y, Han K, Dong X, Hou Q, Li T, Li L, Zhou G, Liu X, Zhao G, Li W. Case report and literature review: primary pulmonary NUT-midline carcinoma. Front Oncol 2021; 11: 700781

[27] Dutta R, Nambirajan A, Mittal S, Roy-Chowdhuri S, Jain D. Cytomorphology of primary pulmonary NUT carcinoma in different cytology preparations. Cancer Cytopathol 2021; 129(1): 53–61

[28] Xie XH, Wang LQ, Qin YY, Lin XQ, Xie ZH, Liu M, Zhang JX, Ouyang M, Liu J, Gu YY, Li SY, Zhou CZ. Clinical features, treatment, and survival outcome of primary pulmonary NUT midline carcinoma. Orphanet J Rare Dis 2020; 15(1): 183

[29] Hung YP, Chen AL, Taylor MS, Huynh TG, Kem M, Selig MK, Nielsen GP, Lennerz JK, Azzoli CG, Dagogo-Jack I, Kradin RL, Mino-Kenudson M. Thoracic nuclear protein in testis (NUT) carcinoma: expanded pathological spectrum with expression of thyroid transcription factor-1 and neuroendocrine markers. Histopathology 2021; 78(6): 896–904

[30] Numakura S, Saito K, Motoi N, Mori T, Saito Y, Yokote F, Kanamoto Y, Asami M, Sakai T, Yamauchi Y, Sakao Y, Uozaki H, Kawamura M. P63-negative pulmonary NUT carcinoma arising in the elderly: a case report. Diagn Pathol 2020; 15(1): 134

[31] Pezzuto F, Fortarezza F, Mammana M, Pasello G, Pelosi G, Rea F, Calabrese F. Immunohistochemical neuroendocrine marker expression in primary pulmonary NUT carcinoma: a diagnostic pitfall. Histopathology 2020; 77(3): 508–510

[32] Cho HJ, Lee HK. Lung nuclear protein in testis carcinoma in an elderly Korean woman: a case report with cytohistological analysis. Thorac Cancer 2020; 11(6): 1724–1727

[33] Lee JK, Louzada S, An Y, Kim SY, Kim S, Youk J, Park S, Koo SH, Keam B, Jeon YK, Ku JL, Yang F, Kim TM, Ju YS. Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma. Ann Oncol 2017; 28(4): 890–897

[34] Cao J, Chen D, Yang F, Yao J, Zhu W, Zhao C. NUT midline carcinoma as a primary lung tumor: a case report. J Thorac Dis 2017; 9(12): E1045–E1049

[35] Lemelle L, Pierron G, Fréneaux P, Huybrechts S, Spiegel A, Plantaz D, Julieron M, Dumoucel S, Italiano A, Millot F, Le Tourneau C, Leverger G, Chastagner P, Carton M, Orbach D. NUT carcinoma in children and adults: a multicenter retrospective study. Pediatr Blood Cancer 2017; 64(12): e26693

[36] Benito Bernáldez C, Romero Muñoz C, Almadana Pacheco V. NUT midline carcinoma of the lung, a rare form of lung cancer. Arch Bronconeumol 2016; 52(12): 619–621

[37] Kuroda S, Suzuki S, Kurita A, Muraki M, Aoshima Y, Tanioka F, Sugimura H. Cytological features of a variant NUT midline carcinoma of the lung harboring the NSD3-NUT fusion gene: a case report and literature review. Case Rep Pathol 2015; 2015: 572951

[38] Nakamura H, Tsuta K, Tsuda H, Katsuya Y, Naka G, Iizuka T, Igari T. NUT midline carcinoma of the mediastinum showing two types of poorly differentiated tumor cells: a case report and a literature review. Pathol Res Pract 2015; 211(1): 92–98

[39] Sholl LM, Nishino M, Pokharel S, Mino-Kenudson M, French CA, Janne PA, Lathan C. Primary pulmonary NUT midline carcinoma: clinical, radiographic, and pathologic characterizations. J Thorac Oncol 2015; 10(6): 951–959

[40] Suzuki S, Kurabe N, Ohnishi I, Yasuda K, Aoshima Y, Naito M, Tanioka F, Sugimura H. NSD3-NUT-expressing midline carcinoma of the lung: first characterization of primary cancer tissue. Pathol Res Pract 2015; 211(5): 404–408

[41] Tanaka M, Kato K, Gomi K, Yoshida M, Niwa T, Aida N, Kigasawa H, Ohama Y, Tanaka Y. NUT midline carcinoma: report of 2 cases suggestive of pulmonary origin. Am J Surg Pathol 2012; 36(3): 381–388

[42] Teo M, Crotty P, O’Sullivan M, French CA, Walshe JM. NUT midline carcinoma in a young woman. J Clin Oncol 2011; 29(12): e336–e339

[43] Badran A, Ali SS, Arabi TZ, Alaklabi AM, Abdalla HM, Mohammed S, Sabbah BN, Elshenawy MA, Atallah JP. Suspected NUT carcinoma progressing on pembrolizumab, carboplatin, and paclitaxel as first-line treatment: a case report. Ann Med Surg (Lond) 2024; 86(2): 1061–1065

[44] Zhao D, Cao W, Zha S, Wang Y, Pan Z, Zhang J, Hu K. Primary pulmonary nuclear protein of the testis midline carcinoma: case report and systematic review with pooled analysis. Front Oncol 2024; 13: 1308432

[45] Zhang KX, Zhang HN, Liu LD, Xu HT. Primary NUT carcinoma of the lung diagnosed by EBUS-TBNA biopsy: a case report. Asian J Surg 2024; 47(6): 2914–2915

[46] Evans AG, French CA, Cameron MJ, Fletcher CD, Jackman DM, Lathan CS, Sholl LM. Pathologic characteristics of NUT midline carcinoma arising in the mediastinum. Am J Surg Pathol 2012; 36(8): 1222–1227

[47] Haack H, Johnson LA, Fry CJ, Crosby K, Polakiewicz RD, Stelow EB, Hong SM, Schwartz BE, Cameron MJ, Rubin MA, Chang MC, Aster JC, French CA. Diagnosis of NUT midline carcinoma using a NUT-specific monoclonal antibody. Am J Surg Pathol 2009; 33(7): 984–991

[48] McLean-Holden AC, Moore SA, Gagan J, French CA, Sher D, Truelson JM, Bishop JA. NUT carcinoma in a patient with unusually long survival and false negative FISH results. Head Neck Pathol 2021; 15(2): 698–703

[49] Shenoy KD, Stanzione N, Caron JE, Fishbein GA, Abtin F, Lluri G, Hirschowitz SL. Midline carcinoma expressing NUT in malignant effusion cytology. Diagn Cytopathol 2019; 47(6): 594–598

[50] Li X, Shi H, Zhang W, Bai C, He M, Ta N, Huang H, Ning Y, Fang C, Qin H, Dong Y. Immunotherapy and targeting the tumor microenvironment: current place and new insights in primary pulmonary NUT carcinoma. Front Oncol 2021; 11: 690115

[51] Giridhar P, Mallick S, Kashyap L, Rath GK. Patterns of care and impact of prognostic factors in the outcome of NUT midline carcinoma: a systematic review and individual patient data analysis of 119 cases. Eur Arch Otorhinolaryngol 2018; 275(3): 815–821

[52] Yin H, Liu Y, Yue H, Tian Y, Dong P, Xue C, Zhao YT, Zhao Z, Wang J. DHA- and EPA-enriched phosphatidylcholine suppress human lung carcinoma 95D cells metastasis via activating the peroxisome proliferator-activated receptor γ. Nutrients 2022; 14(21): 4675

[53] Schwartz BE, Hofer MD, Lemieux ME, Bauer DE, Cameron MJ, West NH, Agoston ES, Reynoird N, Khochbin S, Ince TA, Christie A, Janeway KA, Vargas SO, Perez-Atayde AR, Aster JC, Sallan SE, Kung AL, Bradner JE, French CA. Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res 2011; 71(7): 2686–2696

RIGHTS & PERMISSIONS

Higher Education Press